The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-14-279.
Who won it before
15 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,473,389 in first-year total cost, median $496,455.
Most frequent study sections
- Special Emphasis Panel[ZRG1 MDCN-C (58)]14
- Special Emphasis Panel[ZRG1 MDCN-B (91)]1
Most frequent institutions
- VANDERBILT UNIVERSITY3
- UNIVERSITY OF MICHIGAN AT ANN ARBOR2
- DANA-FARBER CANCER INST1
- OHIO STATE UNIVERSITY1
- OYAGEN, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors1R01GM110119-01A1 | SMITH, HAROLD C | OYAGEN, INC., NY | $601,514 | ZRG1 |
| 2015 | Development of a Novel Inducer for EBV Lytic Therapy1R01CA193624-01 | KENNEY, SHANNON CELESTELIEBERMAN, PAUL M.SALVINO, JOSEPH M | WISTAR INSTITUTE, PA | $591,954 | ZRG1 |
| 2015 | Partial Agonists at Estrogen Receptor alpha for Breast Cancer Therapy1R01CA188017-01A1 | THATCHER, GREGORY R. J | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $485,489 | ZRG1 |
| 2015 | Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy1R01NS088437-01A1 | LI, CHENGLONGYANG, YUHONG | OHIO STATE UNIVERSITY, OH | $471,114 | ZRG1 |
| 2015 | Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction1R01DA037207-01A1 | JONES, CARRIE KIMBERLYLINDSLEY, CRAIG | VANDERBILT UNIVERSITY, TN | $353,142 | ZRG1 |
| 2014 | Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN1R01CA188694-01 | COSFORD, NICHOLAS DAVIDSMITH, JEFFREY W | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $755,282 | ZRG1 |
| 2014 | Inhibition of the Rho/MRTF/SRF Pathway as a New Treatment for Systemic Sclerosis1R01AR066049-01 | LARSEN, SCOTT D | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $655,452 | ZRG1 |
| 2014 | Development and Application of Selective Covalent Cdk7 Inhibitors1R01CA179483-01A1 | GRAY, NATHANAEL SCHIANDERMITSIADES, CONSTANTINE S. | DANA-FARBER CANCER INST, MA | $505,961 | ZRG1 |
| 2014 | Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes1R01EY023725-01A1 | ANTONETTI, DAVID | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $499,870 | ZRG1 |
| 2014 | Optimization of non-peptide probes for the NPFF receptor system1R01DA034777-01A1 | MCCURDY, CHRISTOPHER R | UNIVERSITY OF MISSISSIPPI, MS | $498,705 | ZRG1 |
| 2014 | Discovery of Potent 12-Lipoxygenase Inhibitors of Platelet Activation1R01AG047986-01 | HOLMAN, THEODORE R | UNIVERSITY OF CALIFORNIA SANTA CRUZ, CA | $496,455 | ZRG1 |
| 2014 | Small molecules modulating RNA-binding protein Msi11R01CA178831-01A1 | AUBE, JEFFREYNEUFELD, KRISTI LXU, LIANG | UNIVERSITY OF KANSAS LAWRENCE, KS | $432,491 | ZRG1 |
| 2014 | In vivo probes for the APJ receptor.1R01HD079547-01A1 | MAITRA, RANGANRUNYON, SCOTT P | RESEARCH TRIANGLE INSTITUTE, NC | $427,829 | ZRG1 |
| 2014 | Optimization of modulators of Gbg-SNARE interaction1R01MH101679-01A1 | HAMM, HEIDI ESTAUFFER, SHAUN R | VANDERBILT UNIVERSITY, TN | $400,752 | ZRG1 |
| 2014 | Allosteric modulators of the glucagon-like peptide-1 receptor1R01GM106232-01A1 | DANIELS, JOHN SCOTTLINDSLEY, CRAIGNISWENDER, KEVIN D | VANDERBILT UNIVERSITY, TN | $297,379 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.